{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytoxan", "query": { "intervention": "Cytoxan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2800, "total_pages": 280, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytoxan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:35:06.296Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02601313", "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "brexucabtagene autoleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Axicabtagene Ciloleucel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2015-11-09", "completion_date": "2023-09-22", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 24, "location_summary": "Gilbert, Arizona • Duarte, California • Santa Monica, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601313" }, { "nct_id": "NCT05566223", "title": "CISH Inactivated TILs in the Treatment of NSCLC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Metastatic Non Small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Large Cell Lung Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CISH Inactivated TIL", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2023-02", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 2, "location_summary": "Duarte, California • Minneapolis, Minnesota", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05566223" }, { "nct_id": "NCT00005613", "title": "Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "15 Years to 55 Years" }, "enrollment_count": 147, "start_date": "1996-03", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 2, "location_summary": "Fort Myers, Florida • Tampa, Florida", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005613" }, { "nct_id": "NCT06765317", "title": "A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma (DLBCL)", "High Grade B Cell Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Polatuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Obinutuzumab:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "65 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2025-01-16", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06765317" }, { "nct_id": "NCT00365274", "title": "SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "SGN-30", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2006-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365274" }, { "nct_id": "NCT02280525", "title": "Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "NK Cells", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 8, "start_date": "2015-03-05", "completion_date": "2019-07-09", "has_results": false, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02280525" }, { "nct_id": "NCT06154590", "title": "Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer", "Tumor", "Muscle Neoplasms", "Chronic Pain" ], "interventions": [ { "name": "Method(s)1 Attribution", "type": "DRUG" }, { "name": "Method(s)2 Attribution,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DR. DIANE CHISESI NFS. MD. PHD.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "44 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "44 Years to 59 Years" }, "enrollment_count": 100, "start_date": "2024-07", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 1, "location_summary": "Colorado Springs, Colorado", "locations": [ { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06154590" }, { "nct_id": "NCT00003715", "title": "Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "BCG vaccine", "type": "BIOLOGICAL" }, { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AVAX Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 425, "start_date": "1998-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 17, "location_summary": "Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "North Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003715" }, { "nct_id": "NCT07509008", "title": "Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer, Metastatic" ], "interventions": [ { "name": "TGFBR2 KO CAR27/IL-15 NK cells", "type": "DRUG" }, { "name": "Rimiducid (AP1903)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-09-01", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07509008" }, { "nct_id": "NCT00941720", "title": "Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-06-11", "completion_date": "2013-02-28", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-09-02T10:35:06.296Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941720" } ] }